DURECT Gestione

Gestione criteri di controllo 3/4

DURECT Il CEO è Jim Brown, nominato in Feb1998, e ha un mandato di 26.75 anni. la retribuzione annua totale è $ 1.45M, composta da 40.6% di stipendio e 59.4% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 0.59% delle azioni della società, per un valore di $ 178.93K. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 8.8 anni e 5.6 anni.

Informazioni chiave

Jim Brown

Amministratore delegato

US$1.4m

Compenso totale

Percentuale dello stipendio del CEO	40.6%
Mandato del CEO	26.8yrs
Proprietà del CEO	0.6%
Durata media del management	8.8yrs
Durata media del Consiglio di amministrazione	5.6yrs

Aggiornamenti recenti sulla gestione

Recent updates

Brokers Are Upgrading Their Views On DURECT Corporation (NASDAQ:DRRX) With These New Forecasts

Aug 08

DURECT Corporation (NASDAQ:DRRX) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Mar 10

Does DURECT (NASDAQ:DRRX) Have A Healthy Balance Sheet?

Jan 08

Is DURECT (NASDAQ:DRRX) Using Debt Sensibly?

Aug 05

Durect (DRRX) Investor Presentation - Slideshow

May 06

Durect EPS misses by $0.01, misses on revenue

May 04

DURECT prices ~$43M stock offering

Feb 04

DURECT surges after FDA approval for Posimir

Feb 02

Durect's DUR-928 fast track'd for alcoholic hepatitis in the U.S.

Dec 16

DURECT (DRRX) Investor Presentation - Slideshow

Oct 31

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Jim Brown rispetto agli utili di DURECT?
Data	Compenso totale	Stipendio	Guadagni aziendali
Sep 30 2024	n/a	n/a	-US$17m
Jun 30 2024	n/a	n/a	-US$16m
Mar 31 2024	n/a	n/a	-US$23m
Dec 31 2023	US$1m	US$586k	-US$28m
Sep 30 2023	n/a	n/a	-US$37m
Jun 30 2023	n/a	n/a	-US$36m
Mar 31 2023	n/a	n/a	-US$36m
Dec 31 2022	US$2m	US$575k	-US$35m
Sep 30 2022	n/a	n/a	-US$32m
Jun 30 2022	n/a	n/a	-US$39m
Mar 31 2022	n/a	n/a	-US$37m
Dec 31 2021	US$1m	US$555k	-US$36m
Sep 30 2021	n/a	n/a	-US$38m
Jun 30 2021	n/a	n/a	-US$37m
Mar 31 2021	n/a	n/a	-US$14m
Dec 31 2020	US$1m	US$539k	-US$14m
Sep 30 2020	n/a	n/a	-US$11m
Jun 30 2020	n/a	n/a	-US$3m
Mar 31 2020	n/a	n/a	-US$24m
Dec 31 2019	US$1m	US$531k	-US$21m
Sep 30 2019	n/a	n/a	-US$24m
Jun 30 2019	n/a	n/a	-US$24m
Mar 31 2019	n/a	n/a	-US$24m
Dec 31 2018	US$1m	US$531k	-US$25m
Sep 30 2018	n/a	n/a	-US$10m
Jun 30 2018	n/a	n/a	-US$962k
Mar 31 2018	n/a	n/a	-US$4m
Dec 31 2017	US$1m	US$531k	-US$4m

Compensazione vs Mercato: La retribuzione totale di Jim ($USD 1.45M ) è superiore alla media delle aziende di dimensioni simili nel mercato US ($USD 647.72K ).

Compensazione vs guadagni: La retribuzione di Jim è stata coerente con le performance aziendali dell'ultimo anno.

AMMINISTRATORE DELEGATO

Jim Brown (67 yo)

26.8yrs

Mandato

US$1,445,784

Compensazione

Dr. James E. Brown, also known as Jim, D.V.M., serves as Life Science Advisor since 2021 at K2X Technology & Life Science, Inc. He Co-founded DURECT Corporation in February 1998 and has been its President...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
James Brown	Co-Founder	26.8yrs	US$1.45m	0.59% $ 178.9k
Timothy Papp	CFO & Secretary	2.3yrs	US$671.31k	0% $ 0
Norman Sussman	Chief Medical Officer	4yrs	US$654.48k	0.0029% $ 873.2
Judy Joice	Senior Vice President of Operations & Corporate Quality Assurance	10.7yrs	US$713.55k	Nessun dato
WeiQi Lin	Executive VP of Research & Development and Principal Scientist	no data	Nessun dato	Nessun dato
Jian Li	Senior VP of Finance	23.6yrs	US$452.77k	Nessun dato
Su Yum	Executive Officer	6.8yrs	US$430.63k	Nessun dato

8.8yrs

Durata media

67yo

Età media

Gestione esperta: Il team dirigenziale di DRRX è esperto e expertise (durata media dell'incarico 8.8 anni).

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
James Brown	Co-Founder	26.4yrs	US$1.45m	0.59% $ 178.9k
Gail Maderis	Independent Chairman of the Board	3.8yrs	US$109.74k	0.064% $ 19.4k
Mohammad Azab	Independent Director	3.8yrs	US$81.62k	0.019% $ 5.8k
Terrence Blaschke	Independent Director	17.9yrs	US$83.12k	0.010% $ 3.0k
Peter Garcia	Independent Director	2.9yrs	US$84.73k	0.023% $ 6.8k
Judith Robertson	Independent Director	5.6yrs	US$83.12k	0.11% $ 34.5k
Gail Farfel	Independent Director	5.6yrs	US$70.62k	0.032% $ 9.7k

5.6yrs

Durata media

67yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di DRRX sono considerati esperti (durata media dell'incarico 5.6 anni).

DURECT Gestione

Gestione criteri di controllo 3/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Insufficient new directors

DURECT Corporation, Annual General Meeting, Sep 25, 2024

DURECT Corporation Appoints Timothy M. Papp as Chief Financial Officer

High number of new directors

High number of new directors

DURECT Corporation, Annual General Meeting, Jun 15, 2022

Recent updates

Consensus revenue estimates increase by 62%

Consensus EPS estimates upgraded to US$0.64 loss

Third quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

New major risk - Revenue and earnings growth

DURECT Corporation to Report Q3, 2024 Results on Nov 13, 2024

Consensus revenue estimates decrease by 21%, EPS upgraded

Second quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Insufficient new directors

DURECT Corporation to Report Q2, 2024 Results on Aug 13, 2024

DURECT Corporation, Annual General Meeting, Sep 25, 2024

DURECT Corporation to Report Q1, 2024 Results on May 13, 2024

DURECT Corporation to Report Q4, 2023 Results on Mar 27, 2024

DURECT Receives Non-Compliance Notice from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirement for Continued Listing on the Nasdaq Capital Market

DURECT Corporation to Report Q3, 2023 Results on Nov 13, 2023

DURECT Corporation Announces Topline Results from Phase 2b AHFIRM Trial of Larsucosterol in Alcohol-Associated Hepatitis with Promising Effect on Mortality

Durect Corporation Announces Last Patient Last Visit in Phase 2B Ahfirm Trial of Larsucosterol in Alcohol-Associated Hepatitis

DURECT Corporation to Report Q2, 2023 Results on Aug 09, 2023

DURECT Corporation Completes Enrollment in Phase 2b AHFIRM Trial of Larsucosterol in Alcohol-Associated Hepatitis

DURECT Corporation to Report Q3, 2022 Results on Nov 02, 2022

DURECT Corporation Announces Enrollment of More Than 200 of Planned 300 Patients in is Phase 2b AHFIRM Trial

Innocoll Pharmaceuticals Limited and DURECT Corporation Announce U.S. Launch of POSIMIR

DURECT Corporation Receives Approval from the Listing Qualifications Department of Nasdaq for an Additional 180-Day Grace Period, or Until February 6, 2023

Brokers Are Upgrading Their Views On DURECT Corporation (NASDAQ:DRRX) With These New Forecasts

Price target decreased to US$5.33

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

DURECT Corporation to Report Q2, 2022 Results on Aug 04, 2022

DURECT Corporation Appoints Timothy M. Papp as Chief Financial Officer

Durect names ex-RBC Capital Markets executive as CFO

High number of new directors

Is DURECT (NASDAQ:DRRX) A Risky Investment?

First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

High number of new directors

DURECT Corporation, Annual General Meeting, Jun 15, 2022

Independent Director recently bought US$118k worth of stock

Consensus revenue estimates fall by 16%

DURECT Corporation (NASDAQ:DRRX) Analysts Are More Bearish Than They Used To Be

No longer forecast to breakeven

DURECT Corporation (NASDAQ:DRRX) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

DURECT Corporation Announces Resignation of Michael Arenberg as Chief Financial Officer, Effective March 17, 2022

Durect Corporation Doses First European Patient in Phase 2B Ahfirm Study of Larsucosterol(Dur-928) in Severe Alcohol-Associated Hepatitis

DURECT Corporation to Report Q4, 2021 Results on Mar 07, 2022

Does DURECT (NASDAQ:DRRX) Have A Healthy Balance Sheet?

High number of new directors

Forecast to breakeven in 2024

Third quarter 2021 earnings released: US$0.044 loss per share (vs US$0.046 loss in 3Q 2020)

Price target decreased to US$6.50

Is DURECT (NASDAQ:DRRX) Using Debt Sensibly?

Second quarter 2021 earnings released: US$0.04 loss per share (vs US$0.073 profit in 2Q 2020)

Price target increased to US$7.25

Forecast to breakeven in 2024

DURECT Corporation Presents Additional Clinical Data from DUR-928 Phase 1b Trial in NASH and Phase 1 Trial in Hepatic Impairment at the International Liver Conference 2021

DURECT Corporation to Present Additional Clinical Data from DUR-928 Studies in NASH and in Hepatic Impairment At Upcoming International Liver Conference 2021

Durect (DRRX) Investor Presentation - Slideshow

Durect EPS misses by $0.01, misses on revenue

Durect Corporation Announces Publication of Dur-928'S Mechanism of Action

DURECT Corporation to Report Q4, 2020 Results on Mar 04, 2021

DURECT prices ~$43M stock offering

DURECT Corporation Announces U.S. FDA Approval of POSIMIR® for Post-Surgical Pain Reduction for up to 72 Hours Following Arthroscopic Subacromial Decompression

DURECT surges after FDA approval for Posimir

DURECT Corporation Announces First Patient Dosed in Phase 2b AHFIRM Study of DUR-928 in Severe Alcohol-Associated Hepatitis

DURECT Corporation Announces Board Changes

DURECT Corporation Announces Closing of LACTEL® Absorbable Polymer Product Line Sale to Evonik and Receipt of $15 Million

DURECT Corporation Announces Dur-928 Granted Fda Fast Track Designation for Treatment of Alcoholic Hepatitis

Durect's DUR-928 fast track'd for alcoholic hepatitis in the U.S.

DURECT Corporation Announces Additional Safety Data and Efficacy Signals from Phase 1b Clinical Trial of DUR-928 in NASH Patients at The Liver Meeting Digital Experience 2020

DURECT Corporation Appoints Norman Sussman as Chief Medical Officer

DURECT Corporation Appoints Norman Sussman as Chief Medical Officer

DURECT (DRRX) Investor Presentation - Slideshow